COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors.

abstract：:The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated ...

journal_title：Neuro-oncology

authors： Kreisl TN,Zhang W,Odia Y,Shih JH,Butman JA,Hammoud D,Iwamoto FM,Sul J,Fine HA

更新日期：2011-10-01 00:00:00

abstract：:Neurofibromatosis type 2 (NF2) is an autosomal-dominant disease that results in the formation of bilateral vestibular schwannomas (VSs) and multiple meningiomas. Treatment options for NF2-associated tumors are limited, and to date, no medical therapies are FDA approved. The ideal chemotherapeutic agent would inhibit b...

journal_title：Neuro-oncology

authors： Bush ML,Oblinger J,Brendel V,Santarelli G,Huang J,Akhmametyeva EM,Burns SS,Wheeler J,Davis J,Yates CW,Chaudhury AR,Kulp S,Chen CS,Chang LS,Welling DB,Jacob A

更新日期：2011-09-01 00:00:00

abstract：:The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have led to better systemic control and longer overall patient survi...

journal_title：Neuro-oncology

authors： Arvold ND,Lee EQ,Mehta MP,Margolin K,Alexander BM,Lin NU,Anders CK,Soffietti R,Camidge DR,Vogelbaum MA,Dunn IF,Wen PY

更新日期：2016-08-01 00:00:00

abstract：:Paragangliomas are rare tumors of the paraganglia composed of specialized neural crest cells arising in association with sympathetic ganglia. Here we report a case of progressive, metastatic paraganglioma (glomus jugulare tumor) responsive to single agent gemcitabine. In addition, a brief review of chemotherapy for pa...

journal_title：Neuro-oncology

authors： Pipas JM,Krywicki RF

更新日期：2000-07-01 00:00:00

abstract：:Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too strong toxicity or too little activity. The natural CD95 ligand ...

journal_title：Neuro-oncology

authors： Eisele G,Roth P,Hasenbach K,Aulwurm S,Wolpert F,Tabatabai G,Wick W,Weller M

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Altered expression of micro(mi)RNAs has been shown to be associated with tumorigenesis and tumor progression. The expression of phosphatase and tensin homolog (PTEN) plays an important role in glioma and is regarded as a prognostic marker of glioma patients. The goal of this study was to investigate the func...

journal_title：Neuro-oncology

authors： Wang XR,Luo H,Li HL,Cao L,Wang XF,Yan W,Wang YY,Zhang JX,Jiang T,Kang CS,Liu N,You YP,Chinese Glioma Cooperative Group (CGCG).

更新日期：2013-11-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria...

journal_title：Neuro-oncology

authors： Stelzer KJ,Douglas JG,Mankoff DA,Silbergeld DL,Krohn KA,Laramore GE,Spence AM

更新日期：2008-02-01 00:00:00

abstract：Background:Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods:Using da...

journal_title：Neuro-oncology

authors： Leece R,Xu J,Ostrom QT,Chen Y,Kruchko C,Barnholtz-Sloan JS

更新日期：2017-10-19 00:00:00

abstract：:Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treat...

journal_title：Neuro-oncology

authors： Suppiah S,Nassiri F,Bi WL,Dunn IF,Hanemann CO,Horbinski CM,Hashizume R,James CD,Mawrin C,Noushmehr H,Perry A,Sahm F,Sloan A,Von Deimling A,Wen PY,Aldape K,Zadeh G,International Consortium on Meningiomas.

更新日期：2019-01-14 00:00:00

abstract：:Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates remain poor despite decades of clinical trials of conventional and novel, biologically targeted therapeutics. There is considerable evidence that most of these therapeutics do not reach their targets in the brain when administered...

journal_title：Neuro-oncology

authors： Vogelbaum MA,Aghi MK

更新日期：2015-03-01 00:00:00

abstract：:We explored the feasibility of concurrent palliative chemotherapy and low-dose fractionated radiotherapy (LD-FRT) in glioblastoma multiforme (GBM). Patients with recurrent/progressive GBM at least 3 months after the end of primary radiotherapy received 0.3 Gy twice daily with cisplatin and fotemustine if progressing o...

journal_title：Neuro-oncology

authors： Balducci M,Chiesa S,Diletto B,D'Agostino GR,Mangiola A,Manfrida S,Mantini G,Albanese A,Fiorentino A,Frascino V,De Bari B,Micciche' F,De Rose F,Morganti AG,Anile C,Valentini V

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments. METHODS:Patients with CNS ...

journal_title：Neuro-oncology

authors： Garber ST,Hashimoto Y,Weathers SP,Xiu J,Gatalica Z,Verhaak RG,Zhou S,Fuller GN,Khasraw M,de Groot J,Reddy SK,Spetzler D,Heimberger AB

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:Cisplatin-Induced Peripheral Neuropathy (CIPN) is a frequent serious dose-dependent adverse event that can determine dosage limitations for cancer treatment. CIPN severity correlates with the amount of platinum detected in sensory neurons of the dorsal root ganglia (DRG). However, the exact pathophysiology o...

journal_title：Neuro-oncology

authors： Calls A,Torres-Espin A,Navarro X,Yuste VJ,Udina E,Bruna J

更新日期：2020-06-29 00:00:00

abstract：BACKGROUND:While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recu...

journal_title：Neuro-oncology

authors： Ringel F,Pape H,Sabel M,Krex D,Bock HC,Misch M,Weyerbrock A,Westermaier T,Senft C,Schucht P,Meyer B,Simon M,SN1 study group.

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid...

journal_title：Neuro-oncology

authors： Alimova I,Birks DK,Harris PS,Knipstein JA,Venkataraman S,Marquez VE,Foreman NK,Vibhakar R

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:Accumulation and infiltration of microglia/brain macrophages around and into glioma tissue promote tumor invasion and expansion. One tumor-promoting mechanism of microglia/brain macrophages is upregulation of membrane type 1 matrix metalloprotease (MT1-MMP), which promotes the degradation of extracellular ma...

journal_title：Neuro-oncology

authors： Hu F,Dzaye O,Hahn A,Yu Y,Scavetta RJ,Dittmar G,Kaczmarek AK,Dunning KR,Ricciardelli C,Rinnenthal JL,Heppner FL,Lehnardt S,Synowitz M,Wolf SA,Kettenmann H

更新日期：2015-02-01 00:00:00

abstract：:Diffuse intrinsic pontine glioma (DIPG) has proven to be one of the most challenging of all pediatric cancers. Owing to a historical reticence to obtain tumor tissue for study, and based on an erroneous assumption that the biology of DIPG would mirror that of supratentorial high-grade astrocytomas, innumerable studies...

journal_title：Neuro-oncology

authors： Cohen KJ,Jabado N,Grill J

更新日期：2017-08-01 00:00:00

abstract：Background:Radiomics is a rapidly growing field in neuro-oncology, but studies have been limited to conventional MRI, and external validation is critically lacking. We evaluated technical feasibility, diagnostic performance, and generalizability of a diffusion radiomics model for identifying atypical primary central ne...

journal_title：Neuro-oncology

authors： Kang D,Park JE,Kim YH,Kim JH,Oh JY,Kim J,Kim Y,Kim ST,Kim HS

更新日期：2018-08-02 00:00:00

abstract：:To determine the effectiveness of stereotactic radiosurgery (SRS) treatment to central nervous system (CNS) hemangioblastomas in von Hippel-Lindau disease (VHL), we analyzed long-term results in VHL patients treated with SRS. Patients were enrolled in a prospective VHL natural history study, undergoing SRS treatment o...

journal_title：Neuro-oncology

authors： Asthagiri AR,Mehta GU,Zach L,Li X,Butman JA,Camphausen KA,Lonser RR

更新日期：2010-01-01 00:00:00

abstract：:As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in...

journal_title：Neuro-oncology

authors： Dunn GP,Cloughesy TF,Maus MV,Prins RM,Reardon DA,Sonabend AM

更新日期：2020-10-14 00:00:00

abstract：BACKGROUND:The transcription factor homeobox C9 (HOXC9) plays a crucial role in developmental regulatory systems, where it determines the specific positional identities of cells along the anteroposterior axis. The expression of HOXC9 has been found to be dysregulated in some cancers such as lung cancer, breast cancer, ...

journal_title：Neuro-oncology

authors： Xuan F,Huang M,Liu W,Ding H,Yang L,Cui H

更新日期：2016-06-01 00:00:00

abstract：:Intradural spinal tumors are rare tumors of the central nervous system. Due to the eloquence of the spinal cord and its tracts, the compact architecture of the cord and nerves, and the infiltrative nature of some of these tumors, surgical resection is difficult to achieve without causing neurological deficits. Likewis...

journal_title：Neuro-oncology

authors： Abd-El-Barr MM,Huang KT,Moses ZB,Iorgulescu JB,Chi JH

更新日期：2018-05-18 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...

journal_title：Neuro-oncology

authors： Roth P,Weller M

更新日期：2014-10-01 00:00:00

abstract：:Functional diffusion mapping (fDM) has shown promise as a sensitive imaging biomarker for predicting survival in initial studies consisting of a small number of patients, mixed tumor grades, and before routine use of anti-angiogenic therapy. The current study tested whether fDM performed before and after radiochemothe...

journal_title：Neuro-oncology

authors： Ellingson BM,Cloughesy TF,Zaw T,Lai A,Nghiemphu PL,Harris R,Lalezari S,Wagle N,Naeini KM,Carrillo J,Liau LM,Pope WB

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors ...

journal_title：Neuro-oncology

authors： Capdevielle C,Desplat A,Charpentier J,Sagliocco F,Thiebaud P,Thézé N,Fédou S,Hooks KB,Silvestri R,Guyonnet-Duperat V,Petrel M,Raymond AA,Dupuy JW,Grosset CF,Hagedorn M

更新日期：2020-04-15 00:00:00

abstract：:A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks.1 Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades.2 These r...

journal_title：Neuro-oncology

authors： Chiocca EA,Nassiri F,Wang J,Peruzzi P,Zadeh G

更新日期：2019-01-01 00:00:00

abstract：:Survival alone is no longer an adequate outcome for persons with brain tumors; the quality of the survivorship experience should be viewed with equal importance. Symptom management is a significant component of quality survivorship care. Regardless of their histology, brain tumors and therapies used to treat them prod...

journal_title：Neuro-oncology

authors： Amidei C

更新日期：2018-11-09 00:00:00

abstract：:Brain metastasis, which occurs in 20% to 40% of all cancer patients, is an important cause of neoplastic morbidity and mortality. Successful invasion into the brain by tumor cells must include attachment to microvessel endothelial cells, penetration through the blood-brain barrier, and, of relevance, a response to bra...

journal_title：Neuro-oncology

authors： Denkins Y,Reiland J,Roy M,Sinnappah-Kang ND,Galjour J,Murry BP,Blust J,Aucoin R,Marchetti D

更新日期：2004-04-01 00:00:00

abstract：Background:Glioblastoma cell-initiated vascularization is an alternative angiogenesis called vasculogenic mimicry. However, current knowledge on the mechanism of de novo vessel formation from glioblastoma stem cells (GSCs) is limited. Methods:Sixty-four glioblastoma samples from patients and 10 fluorescent glioma xeno...

journal_title：Neuro-oncology

authors： Mei X,Chen YS,Chen FR,Xi SY,Chen ZP

更新日期：2017-08-01 00:00:00

abstract：:Data on spinal ependymomas are sparse, and prognostic factors remain controversial. The primary aim of this study is to review a historical cohort, with large patient numbers and long follow-up, and provide estimates of time to progression (TTP) and survival after progression. As a secondary aim, we assess the effects...

journal_title：Neuro-oncology

authors： Gomez DR,Missett BT,Wara WM,Lamborn KR,Prados MD,Chang S,Berger MS,Haas-Kogan DA

更新日期：2005-07-01 00:00:00